PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

被引：0
|
作者：
Black, J. D. [1 ]
Lopez, S. [1 ]
Cocco, E. [1 ]
Bellone, S. [1 ]
Altwerger, G. [1 ]
Schwab, C. L. [1 ]
English, D. P. [1 ]
Bonazzoli, E. [1 ]
Predolini, F. [1 ]
Ferrari, F. [1 ]
Ratner, E. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Schwartz, P. E. [1 ]
Santin, A. D. [1 ]
机构：
[1] Yale Univ, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 139卷 / 03期
关键词：
D O I：
10.1016/j.ygyno.2015.09.058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：596 / 596
页数：1
相关论文
共 50 条
  • [21] Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
    Lopez, Salvatore
    Cocco, Emiliano
    Black, Jonathan
    Bellone, Stefania
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Schwab, Carlton L.
    English, Diana P.
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Terranova, Corrado
    Angioli, Roberto
    Santin, Alessandro D.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) : 2519 - 2526
  • [22] Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
    Hernandez, Silvia F.
    Chisholm, Sarah
    Borger, Darrell
    Foster, Rosemary
    Rueda, Bo R.
    Growdon, Whitfield B.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (03) : 570 - 579
  • [23] Adding trastuzumab to carboplatin and paclitaxel improves overall survival in advanced-stage HER2/NEU overexpressing uterine serous carcinoma or carcinosarcoma
    Lu, Ting-Fang
    Lou, Sun
    Shih, Yu-Hsiang
    Chen, Yen-Fu
    Fan, Chun Ting
    Wang, Shao-Jing
    Hsu, Shih-Tien
    Liu, Chin-Ku
    Hwang, Sheau-Feng
    Lu, Chien-Hsing
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A45 - A46
  • [24] Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
    English, Diana P.
    Bellone, Stefania
    Cocco, Emiliano
    Bortolomai, Ileana
    Pecorelli, Sergio
    Lopez, Salvatore
    Silasi, Dan-Arin
    Schwartz, Peter E.
    Rutherford, Thomas
    Santin, Alessandro D.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 209 (05)
  • [25] HER2, EGFR, PIK3CA mutations in HER2+metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
    Gori, S.
    Ludovini, V.
    Colozza, M.
    Pistola, L.
    Tofanetti, F. R.
    Flacco, A.
    Foglietta, J.
    Minenza, E.
    Stocchi, L.
    De Angelis, V.
    Crino, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [27] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [28] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Mothaffar F. Rimawi
    Carmine De Angelis
    Alejandro Contreras
    Fresia Pareja
    Felipe C. Geyer
    Kathleen A. Burke
    Sabrina Herrera
    Tao Wang
    Ingrid A. Mayer
    Andres Forero
    Rita Nanda
    Matthew P. Goetz
    Jenny C. Chang
    Ian E. Krop
    Antonio C. Wolff
    Anne C. Pavlick
    Suzanne A. W. Fuqua
    Carolina Gutierrez
    Susan G. Hilsenbeck
    Marilyn M. Li
    Britta Weigelt
    Jorge S. Reis-Filho
    C. Kent Osborne
    Rachel Schiff
    Breast Cancer Research and Treatment, 2018, 167 : 731 - 740
  • [29] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Rimawi, Mothaffar F.
    De Angelis, Carmine
    Contreras, Alejandro
    Pareja, Fresia
    Geyer, Felipe C.
    Burke, Kathleen A.
    Herrera, Sabrina
    Wang, Tao
    Mayer, Ingrid A.
    Forero, Andres
    Nanda, Rita
    Goetz, Matthew P.
    Chang, Jenny C.
    Krop, Ian E.
    Wolff, Antonio C.
    Pavlick, Anne C.
    Fuqua, Suzanne A. W.
    Gutierrez, Carolina
    Hilsenbeck, Susan G.
    Li, Marilyn M.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 731 - 740
  • [30] Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone Development
    Amri, Raja
    Charfi, Slim
    Jema, Mohamed
    Miled, Nabil
    Slimi, Fathia
    Rebai, Mohamed Ali
    Abdelwahed, Mayssa
    Keskes, Hassib
    Aifa, Sami
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
12345